← Back to headlines
CalciMedica Stock Rises on Pulmonary Hypertension Progress Despite Q2 Earnings Miss
CalciMedica's stock gained 6% as progress in its pulmonary hypertension research offset a miss in its second-quarter earnings report.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
